FiercePharma  Apr 24  Comment 
It’s been a painful few years for Orexigen Therapeutics in the obesity arena, and the company is finally ready to bow out. The San Diego-based drugmaker has inked a pact with Nalpropion Pharmaceuticals—a new company funded in part by specialty...
Wall Street Journal  Mar 12  Comment 
Drugmaker Orexigen filed for bankruptcy protection on Monday and plans to sell itself, after failing to find a profitable market for its weight-loss treatment Contrave.
FierceBiotech  Mar 12  Comment 
Orexigen Therapeutics is filing for bankruptcy and plans to auction off its obesity med, Contrave, to pay down its debt.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki